ZG19018
/ Suzhou Zelgen
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 01, 2024
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
(clinicaltrials.gov)
- P1/2 | N=110 | Recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS
April 27, 2023
First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.
(ASCO 2023)
- "ZG19018 is tolerable and demonstrates a good safety under the dose level of 450 mg bid. It also demonstrates preliminary antitumor effects in pts with solid tumors, with reasonable PK profiles. Clinical trial information: ChiCTR20220296."
Clinical • Metastases • Monotherapy • P1 data • Cervical Cancer • Colorectal Cancer • Dyslipidemia • Gastrointestinal Cancer • Hypertriglyceridemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS
March 14, 2023
Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced non-small cell lung cancer and other solid tumors
(AACR 2023)
- "Growing evidences of covalent irreversible inhibitors in clinical treatments of solid tumors with KRAS G12C mutation have recently emerged after FDA-approved AMG510 (Sotorasib) for NSCLC chemotherapies. The genotoxic potential studies indicated ZG19018 without mutagenesis. Collectively, ZG19018 is now in phase I/II clinical trials for the treatments of solid tumors with KRAS G12C mutation in China."
Metastases • Preclinical • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS
December 29, 2021
Zejing Pharmaceutical's new drug for the treatment of non-small cell lung cancer was approved for clinical trials [Google translation]
(Eastmoney.com)
- "On December 29, Zejing Pharmaceutical announced that ZG19018 tablets for the treatment of advanced malignant solid tumors have been approved by the State Food and Drug Administration to start clinical trials."
New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1